Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Ronald, D'Amico"'
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Qinglu Cheng, Evan B. Cunningham, Sophy Shih, Janaki Amin, Julie Bruneau, Adelina A. Artenie, Jeff Powis, Alain H. Litwin, Curtis Cooper, Olav Dalgard, Margaret Hellard, Philip Bruggmann, Philippa Marks, Karine Lacombe, Catherine Stedman, Phillip Read, Behzad Hajarizadeh, Adrian J. Dunlop, Brian Conway, Jordan J. Feld, Gregory J. Dore, Jason Grebely, Gregory Dore, Sione Crawford, Tracy Swan, Jude Byrne, Melanie Lacalamita. Coordinating Centre—Amanda Erratt, Evan Cunningham, Pip Marks, Ineke Shaw, Sharmila Siriragavan, Sophie Quiene, Kathy Petoumenos, Patrick Schmid, Erika Castro, Alberto Moriggia, Jean-Pierre Daulouede, Christopher Fraser, Jordan Feld, Ed Gane, Gail Matthews, Adrian Dunlop, Ian Kronborg, David Shaw, Alain Litwin, Brianna Norton, Maria Christine Thurnheer, Martin Weltman, Philip Read, John Dillon, Simone Kessler, Cornelia Knapp, Lorenza Oprandi, Paola Messina, Marzia Pantic, Manuela Le Cam, Cecilia Maitre, Jessica Andreassen, Ingunn Melkeraaen, Merete Moen Tollefsen, Hannah Pagarigan, Rozalyn Milne, Kate Mason, Diana Kaznowski, Lily Zou, Rachel Bouchard, Barbara Kotsoros, Miriam Muir, Jessica Milloy, Victoria Oliver, Tracy Noonan, Alison Sevehon, Susan Hazelwood, Michelle Hall, Michelle Hagenauer, Rachel Liddle, Catherine Ferguson, Linda Agyemang, Hiral Patel, Irene Soloway, Orlando Cerocchi, Melanie Lacalamita, Vincenzo Fragomeli, Rosie Gilliver, Rebecca Lothian, Shirley Cleary, Linda Johnston, Sarah Middleton, Ronald D’Amico, Barbara McGovern, Jonathan Anderson, Ze Zhong, Fiona Keane, Fernando Tatsch, Diana Brainard, John McHutchison
Publikováno v:
Value in Health. 26:883-892
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ee5950dc9b00953ac5284758ffc480d
https://doi.org/10.1016/j.jval.2022.12.016
https://doi.org/10.1016/j.jval.2022.12.016
Autor:
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Alexander Wong, Norma Porteiro, Susan Swindells, Jacques Reynes, Sebastian Noe, Conn Harrington, Carlos Martín Español, Carolina Acuipil, Asma Aksar, Yuanyuan Wang, Susan L Ford, Herta Crauwels, Veerle van Eygen, Rodica Van Solingen-Ristea, Christine L Latham, Shanker Thiagarajah, Ronald D’Amico, Kimberly Y Smith, Kati Vandermeulen, William R Spreen
Publikováno v:
Clinical Infectious Diseases. 76:1646-1654
Background Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::827332ee0cdd16ef2762c9918822e648
https://doi.org/10.1093/cid/ciad020
https://doi.org/10.1093/cid/ciad020
Autor:
Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna, Peter Messiaen, Maria Jose Galindo Puerto, Mark Bloch, Eisuke Adachi, Gary Sinclair, Franco Felizarta, Jonathan B. Angel, Kenneth Sutton, Denise Sutherland-Phillips, Ronald D'Amico, Deanna Kerrigan
Publikováno v:
AIDS Patient Care and STDs. 37:53-59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c891dd232877d261b46a7bd732a0e02f
https://doi.org/10.1089/apc.2022.0168
https://doi.org/10.1089/apc.2022.0168
Autor:
Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D'Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William R. Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari
Publikováno v:
HIV Medicine. 24:568-579
Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout data in those exposed to CAB + RPV long-acting (LA) with live
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43bf1b21883d14b167f9758f11284da5
https://doi.org/10.1111/hiv.13439
https://doi.org/10.1111/hiv.13439
Autor:
Ronald D'Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen‐Ristea, Bryan Baugh, Erika Van Landuyt, Veerle Van Eygen, Sherene Min, Amy Cutrell, Caroline Foster, Daniella Chilton, Sabine D. Allard, Annemiek Ruiter
Publikováno v:
HIV Medicine. 24:202-211
OBJECTIVES: Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen. Outcomes are reported. METH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18eb00daa191b15c2cc0dadc822b25d7
https://doi.org/10.1111/hiv.13370
https://doi.org/10.1111/hiv.13370
Autor:
Maggie, Czarnogorski, Paul, Benn, Cindy, McCoig, Toyin, Nwafor, Sandy, Griffith, Ken, Sutton, Conn, Harrington, Parminder, Saggu, Itziar, Yague, Will, Williams, Carlos M, Español, Jessica, Goodchild, Jane, Fricker, Parul, Patel, Ronald, D'Amico
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 91:157-161
Cabotegravir + rilpivirine long-acting (LA) is a novel antiretroviral therapy (ART) administered intramuscularly monthly or every 2 months by a health care provider. The COVID-19 pandemic presents a potential challenge to patients' ability to attend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8eeef90b4563429c376ebc54511390b
https://doi.org/10.1097/qai.0000000000003031
https://doi.org/10.1097/qai.0000000000003031
Autor:
Parul Patel, Emilie Elliot, Ronald D’Amico, Louise Garside, Conor Smith, Jeremy Roberts, Joseph W Polli, Moti Ramgopal, Princy N Kumar, Olayemi Osiyemi, Bryan Baugh, Jean A van Wyk
Publikováno v:
Open Forum Infectious Diseases. 9
Background Long-acting cabotegravir + rilpivirine (CAB + RPV LA) administered monthly or every 2 months is the first and only complete LA regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. This post hoc an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18bfb8f7f84050add430c8fc8cbaf7a3
https://doi.org/10.1093/ofid/ofac492.109
https://doi.org/10.1093/ofid/ofac492.109
Autor:
Cindy P, Garris, Maggie, Czarnogorski, Marybeth, Dalessandro, Ronald, D'Amico, Toyin, Nwafor, Will, Williams, Deanna, Merrill, YuanYuan, Wang, Larissa, Stassek, Michael B, Wohlfeiler, Gary I, Sinclair, Leandro A, Mena, Blair, Thedinger, Jason A, Flamm, Paul, Benson, William R, Spreen
Publikováno v:
Journal of the International AIDS Society. 25
The CUSTOMIZE hybrid III implementation-effectiveness study evaluated implementation of once-monthly long-acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1771ebb01ec7de370146e12aec53d4f5
https://doi.org/10.1002/jia2.26006
https://doi.org/10.1002/jia2.26006
Autor:
Jerry L. Jeffrey, Marty St. Clair, Ping Wang, Chunfu Wang, Zhufang Li, Jagadish Beloor, Christine Talarico, Robert Fridell, Mark Krystal, C. Thomas White, Sandy Griffith, Ronald D’Amico, Kimberly Smith, Veerle Van Eygen, Johan Vingerhoets, Kati Vandermeulen, William Spreen, Jan van Lunzen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::853db3a1c7425ded74759ab3715e3787
https://doi.org/10.1128/aac.01702-21
https://doi.org/10.1128/aac.01702-21